Dermatol. praxi. 2021;15(4):207-211 | DOI: 10.36290/der.2021.038

Lyme disease currently

MUDr. Dita Smíšková, Ph.D.1, 2, doc. MUDr. Dušan Pícha, CSc.1
1 Klinika infekčních nemocí 2. LF UK a Nemocnice Na Bulovce, Praha
2 Klinika infekčních, parazitárních a tropických nemocí, Nemocnice Na Bulovce, Praha

Lyme borreliosis is the most common tick-borne infection in Central Europe. Borrelia have an affinity for a number of organs and tissues (skin, nervous system, joints, myocardium, etc.). The basis of laboratory diagnosis is currently the detection of specific IgM and IgG antibodies, confirming contact with the infectious agent, not the activity of the infection. Other methods are of limited use mainly due to low sensitivity (PCR) or lack of clinical data (specific cellular immune response). Careful evaluation of the clinical symptoms in correlation with laboratory test results is a prerequisite for a correct diagnosis. In the early stages of the disease, the effect of antibiotic treatment is very good. Inadequate or no clinical response should lead to a reassessment of the diagnosis and extension of the diagnostic procedures to other, even non-infectious causes of the symptoms. Newly developed vaccines could contribute to the prevention of the disease in the future.

Keywords: lyme disease, erythema migrans, Bannwarth syndrome, neuroborreliosis, diagnostics, treatment.

Published: November 23, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smíšková D, Pícha D. Lyme disease currently. Dermatol. praxi. 2021;15(4):207-211. doi: 10.36290/der.2021.038.
Download citation

References

  1. Wilhelmsson P, Fryland L, Lindblom P, et al. A prospective study on the incidence of Borrelia burgdorferi sensu lato infection after a tick bite in Sweden and on the Aland Islands, Finland (2008-2009). Ticks Tick Borne Dis. 2016; 7(1): 71-79. Go to original source... Go to PubMed...
  2. Radolf JD, Caimano MJ, Stevenson B, et al. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nature Reviews Microbiology 2012; 10(2): 87-99. Go to original source... Go to PubMed...
  3. Krupka M, Raska M, Belakova J, et al. Biological aspects of Lyme disease spirochetes: unique bacteria of the Borrelia burgdorferi species group. Biomed Pap. Czech Repub. 2007; 151(2): 175-186. Go to original source... Go to PubMed...
  4. Steere AC, Klitz W, Drouin EE, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006; 203(4): 961-971. Go to original source... Go to PubMed...
  5. Lochhead RB, Strle K, Arvikar SL, et al. Lyme arthritis: linking infection, inflammation and autoimmunity. Nat Rev Rheumatol. 2021; 17(8): 449-461. Go to original source... Go to PubMed...
  6. Prasad A, Sankar D. Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable. Postgrad Med J. 1999; 75(889): 650-656. Go to original source... Go to PubMed...
  7. Knudtzen FC, Andersen NS, Jensen TG, et al. Characteristics and Clinical Outcome of Lyme Neuroborreliosis in a High Endemic Area, 1995-2014: A Retrospective Cohort Study in Denmark. Clin Infect Dis. 2017; 65(9): 1489-1495. Go to original source... Go to PubMed...
  8. Ogrinc K, Lusa L, Lotric-Furlan S, et al. Course and Outcome of Early European Lyme Neuroborreliosis (Bannwarth Syndrome): Clinical and Laboratory Findings. Clin Infect Dis. 2016; 63(3): 346-353. Go to original source... Go to PubMed...
  9. Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011; 17(1): 69-79. Go to original source... Go to PubMed...
  10. Krbkova L, Kybicova K, Picha D, et al [Guideline for the diagnosis and treatment of Lyme borreliosis]. Klin Mikrobiol Infekc Lek. 2018; 24(3): 88-99. Go to PubMed...
  11. Ornstein K, Berglund J, Bergstrom S, et al. Three major Lyme Borrelia genospecies (Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii) identified by PCR in cerebrospinal fluid from patients with neuroborreliosis in Sweden. Scand J Infect Dis. 2002; 34(5): 341-346. Go to original source... Go to PubMed...
  12. Cerar T, Ogrinc K, Cimperman J, et al. Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. J Clin Microbiol. 2008; 46(10): 3375-3379. Go to original source... Go to PubMed...
  13. Moore A, Nelson C, Molins C, et al. Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States. Emerg Infect Dis. 2016; 22(7). Go to original source... Go to PubMed...
  14. Picha D, Moravcova L, Vanousova D, et al. DNA persistence after treatment of Lyme borreliosis. Folia Microbiol. 2014; 59(2): 115-125. Go to original source... Go to PubMed...
  15. Tuuminen T, Hedman K, Söderlund-Venermo M, et al. Acute Parvovirus B19 Infection Causes Nonspecificity Frequently in Borrelia and Less Often in Salmonella and Campylobacter Serology, Posing a Problem in Diagnosis of Infectious Arthropathy. Clinical and Vaccine Immunology: CVI. 2011; 18(1): 167-172. Go to original source... Go to PubMed...
  16. Van Gorkom T, Sankatsing SUC, Voet W, et al. An Enzyme-Linked Immunosorbent Spot Assay Measuring Borrelia burgdorferi B31-Specific Interferon Gamma-Secreting T Cells Cannot Discriminate Active Lyme Neuroborreliosis from Past Lyme Borreliosis: a Prospective Study in the Netherlands. J Clin Microbiol. 2018; 56(4). Go to original source... Go to PubMed...
  17. Rupprecht TA, Manz KM, Fingerle V, et al. Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis. Clin Microbiol Infect. 2018; 24(12): 1234-1240. Go to original source... Go to PubMed...
  18. Picha D, Moravcova L, Smiskova D. Prospective study on the chemokine CXCL13 in neuroborreliosis and other aseptic neuroinfections. J Neurol Sci. 2016; 368: 214-220. Go to original source... Go to PubMed...
  19. Pietikainen A, Oksi J, Hytonen J. Point-of-care testing for CXCL13 in Lyme neuroborreliosis. Diagn Microbiol Infect Dis. 2018; 91(3): 226-228. Go to original source... Go to PubMed...
  20. Wagner JN, Weis S, Kubasta C, et al. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients. J Neurol. 2018; 265(1): 74-81. Go to original source... Go to PubMed...
  21. Delong AK, Blossom B, Maloney EL, et al. Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials. Contemp Clin Trials. 2012; 33(6): 1132-1142. Go to original source... Go to PubMed...
  22. Holzbauer SM, Kemperman MM, Lynfield R. Death due to community-associated Clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected lyme disease. Clin Infect Dis. 2010; 51(3): 369-370. Go to original source... Go to PubMed...
  23. Comstedt P, Schuler W, Meinke A,et al. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One. 2017; 12(9): e0184357. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.